共 21 条
- [21] Real-world (rw) clinical outcomes for advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) treated with second line (2L) ramucirumab plus docetaxel (R plus D) post frontline (1L) platinum based chemotherapy plus immune checkpoint inhibitors (Pt plus ICI). JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)